In
HIV and ID Observations, Dr. Paul Sax discusses the approval of a brand new antibiotic class for treatment of uncomplicated urinary tract infections.
“Gepotidacin” sounds like the name of a rare tropical bird. But, says Dr. Paul Sax, it's something rarer — and arguably more exciting. It's a first-in-class triazaacenaphthylene antibiotic, approved by the FDA on March 25 for the treatment of uncomplicated urinary tract infections. Read more in the latest HIV and ID Observations.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Follow Via Email box.
Want to see more from NEJM Journal Watch? Register here.